Merck & Co. Receives Consensus Rating of “Hold” from Analysts (NYSE:MRK)
Shares of Merck & Co. (NYSE:MRK) have earned a consensus rating of “Hold” from the eighteen analysts that are currently covering the company, AmericanBankingNews.com reports. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $60.80.
Shares of Merck & Co. (NYSE:MRK) opened at 60.32 on Wednesday. Merck & Co. has a 52 week low of $44.62 and a 52 week high of $60.40. The stock’s 50-day moving average is $58.01 and its 200-day moving average is $57.12. The company has a market cap of $174.0 billion and a price-to-earnings ratio of 31.72. Merck & Co. also was the target of some unusual options trading on Monday. Traders bought 5,003 put options on the company. This is an increase of approximately 111% compared to the average volume of 2,366 put options.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.85 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.80 by $0.05. The company had revenue of $10.93 billion for the quarter, compared to the consensus estimate of $10.60 billion. During the same quarter last year, the company posted $0.84 earnings per share. Merck & Co.’s revenue was down .7% compared to the same quarter last year. On average, analysts predict that Merck & Co. will post $3.49 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a dividend yield of 2.92%. The ex-dividend date is Thursday, September 11th.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Merck & Co. in a research note on Wednesday. They set a “hold” rating and a $63.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co. in a research note on Monday, August 18th. They now have a $62.00 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Merck & Co. from $63.00 to $60.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock.
In other Merck & Co. news, EVP Adam H. Schechter sold 22,000 shares of the stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $59.70, for a total transaction of $1,313,400.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Merck & Co, Inc (NYSE:MRK), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Receive News & Ratings for Merck & Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.